BioWorld Asia

Feb. 11, 2004

Ark Seeks Listing On London Stock Exchange Via £50 IPO

LONDON - Ark Therapeutics Group plc is feeling out investor appetite for what would be the first listing of a biotechnology company on the main market of the London Stock Exchange in three years. (BioWorld International) Read More

CAT Reports CAT-192 Results With Genzyme, Ends Elan Deal

Structure Of 1918 Flu Virus Holds Clue To Its Virulence

Hurdles For Europe Include Tissue Engineering, Patents

Advancements In SiRNA Spur Strategy Change For Atugen

BiondVax Raises $4M For Multiseason Nasal Vaccine

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 26, 2026.

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

Next wave of BCI firms builds on pioneers to tackle challenges

BioWorld

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...

Boehringer Ingelheim identifies new mGlu3 receptor agonists

BioWorld Science

Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...